Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
LabGenius is a pioneering synthetic biology company leveraging machine learning (ML), robotic automation, and synthetic DNA to evolve and discover novel therapeutic proteins. Their proprietary platform, EVA™, integrates these technologies to navigate vast protein design spaces, aiming to dramatically accelerate the discovery of next-generation biologics. LabGenius focuses on identifying high-performing antibodies and other protein-based therapeutics with enhanced efficacy, safety, and developability profiles, addressing complex diseases with significant unmet medical needs. They partner with pharmaceutical and biotech companies to co-develop these advanced therapies.
The London headquarters serves as the central hub for LabGenius's research and development, including its advanced wet labs, robotic automation facilities, machine learning model development, and corporate operations. It's where the core scientific and technological innovation takes place.
Features state-of-the-art, custom-designed wet lab facilities integrated with high-throughput robotic automation systems and extensive computational infrastructure. The space is designed to foster collaboration between multidisciplinary teams of biologists, data scientists, and engineers.
LabGenius promotes a highly innovative, collaborative, and science-driven work culture. Employees often describe it as dynamic and intellectually stimulating, with a strong emphasis on interdisciplinary teamwork, problem-solving, and pushing the boundaries of protein engineering.
The headquarters is strategically located in London, a major global hub for biotechnology and artificial intelligence, providing access to talent, academic collaborations, and investment. It's the birthplace and operational center of their EVA™ platform.
While LabGenius's physical operations and R&D are primarily centralized in their London headquarters, their impact and collaborations are global. They partner with international pharmaceutical and biotech companies to co-develop therapeutics and engage with the global scientific community through research publications and conferences. Their drug discovery efforts aim to address diseases affecting populations worldwide.
20 Micawber Street
London
England
United Kingdom
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, LabGenius' leadership includes:
LabGenius has been backed by several prominent investors over the years, including:
LabGenius has strategically strengthened its executive leadership over the past 12-18 months with key appointments in scientific, financial, and technological roles to support its growth and scaling of its AI-driven drug discovery platform. No major executive departures have been publicly announced during this period.
Discover the tools LabGenius uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
LabGenius most likely utilizes common professional email formats. Based on typical industry standards and executive contact information, the primary format appears to be [first].[last]@labgeni.us.
[first].[last]@labgeni.us
Format
james.field@labgeni.us
Example
90%
Success rate
GlobeNewswire • June 7, 2023
LabGenius entered into a multi-year strategic research collaboration with Abzena, a partner research organization. The collaboration aims to co-develop novel therapeutic antibodies by combining LabGenius's ML-driven EVA™ platform with Abzena's expertise in antibody discovery and developability....more
Business Wire • May 10, 2023
LabGenius announced the appointment of Alison Hueber as its Chief Financial Officer. Ms. Hueber brings over 20 years of experience in financial leadership within the life sciences and technology sectors....more
PR Newswire • April 19, 2023
LabGenius appointed Dr. Gino Van Heeke as Chief Scientific Officer. Dr. Van Heeke has an extensive background in drug discovery, having held senior roles at major pharmaceutical companies, and will lead LabGenius's scientific strategy....more
Atomico (via Medium) • October 25, 2022
LabGenius announced a £35 million (approximately $40 million) Series B funding round. The round was co-led by M Ventures (the corporate venture capital arm of Merck KGaA, Darmstadt, Germany) and Octopus Ventures, with participation from existing investors including Atomico and Lux Capital. The funds will be used to expand its team, further develop its EVA™ platform, and advance its pipeline of novel antibody therapeutics....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including LabGenius, are just a search away.